Please login to the form below

Not currently logged in
Email:
Password:

Chase adds former Allergan execs to leadership team

Scott Giacobello and Gary Charbonneau join

Chase Pharmaceuticals Scott GiacobelloCalifornian Chase Pharmaceuticals has made two appointments to its senior leadership team.

Scott Giacobello (pictured right) becomes chief financial officer at the clinical-stage biopharma company, bringing almost 25 years of experience in finance and accounting.

Most recently, Giacobello served as vice president of finance for global research and development at Allergan, and has held financial positions at Black & Decker and Ernst & Young.

Meanwhile, Gary Charbonneau (pictured below) has been appointed as senior vice president for regulatory affairs and operations.

Charbonneau joins Chase with over 25 years of experience in regulatory, quality and research and development operations.

He moves from Allergan, where he spent 14 years in a number of senior regulatory positions, including his most recent role as vice president of international regulatory affairs.

Chase Pharmaceuticals Gary CharbonneauCharbonneau also brings experience from Amgen, Baxter, Novo Nordisk and Roche

Douglas Ingram, chief executive officer at Chase, said: “I could not be more delighted to welcome Scott and Gary to Chase.

“With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease.

“Scott and Gary have the proven track records, enthusiasm and commitment to operational excellence that will help Chase succeed in improving the lives of millions of patients suffering from this devastating disease.”

20th June 2016

From: Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...